Press Releases

Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016

June 9, 2016 at 7:30 AM EDT

- Presentation of GEN-003 12-Month Data Featured in ASM Press Briefing -

- Phase 2 GEN-004 Results Highlight Potential for Future Development of Vaccine for Pneumococcal Disease -

CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, will present updated data on the company's investigational immunotherapies at the American Society for Microbiology annual general meeting, ASM Microbe 2016, June 16-20, 2016 in Boston.

"We are excited to highlight the data from our Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. The statistically significant reductions in viral shedding and sustained efficacy 12 months after completion of dosing suggest GEN-003 could become a cornerstone therapy for patients suffering from genital herpes," said Chip Clark, president and chief executive officer of Genocea. "Additionally, the trends seen in reducing nasopharyngeal colonization in the Phase 2a trial of GEN-004 for the treatment of pneumococcal disease demonstrates the potential of the vaccine's concept, which we hope will lead to a partnership to advance this program."

Genocea data to be presented at ASM Microbe 2016 include:


  • PW-039: GEN-003, a Therapeutic Vaccine for Genital Herpes, Significantly Reduces Viral Shedding and Lesions for at Least 6 Months

    Poster walk on Sunday, June 19, 2016, 12:30 — 1:30 p.m. ET
    BCEC, Exhibit and Poster Hall, Halls A and B

    Poster on Monday, June 20, 2016, 12:30 — 2:30 p.m. ET 
    BCEC, Exhibit and Poster Hall, Halls A and B


  • GEN-004, a Recombinant Protein-based Vaccine, Protects Against Colonization with Streptococcus pneumoniae Strains 6b and 23f in an Il-17a-Dependent Manner

    Slide session on Friday, June 17, 2016, 4:00 — 4:15 p.m. ET
    BCEC, Meeting Room 154
  • Pneumococcal Protein Vaccine Gen-004 Reduces Experimental Human Pneumococcal Carriage in Healthy Adults

    Poster presentation on Monday, June 20, 2016, 12:30 — 2:30 p.m. ET 
    BCEC, Exhibit and Poster Hall, Halls A and B

About GEN-003
Inducing a T cell response against HSV-2 is critical to treating the clinical symptoms of disease and controlling transmission of the infection. GEN-003 is a first-in-class T-cell directed immunotherapy designed to elicit both a T cell and B cell (antibody) immune response. The immunotherapy was designed using Genocea's ATLAS™ platform, which profiles the comprehensive spectrum of actual T cell responses mounted by humans in response to disease, to identify antigen targets that drive T cell response. GEN-003 includes the antigens ICP4 and gD2 along with Matrix-M2TM adjuvant, which Genocea licensed from Novavax, Inc. For more information about GEN-003, please visit

About Genital Herpes
Genital Herpes affects more than 400 million people worldwide and causes recurrent, painful genital lesions. It can be transmitted to sexual partners, even when the disease is asymptomatic. Current genital herpes therapies only partially control clinical symptoms and viral shedding, a process which drives disease transmission. Incomplete control of genital lesions and transmission risk, expense and the perceived inconvenience of taking a daily medication are hurdles for long-term disease management. Immunity through T cells is believed to be particularly critical to the control and possible prevention of genital herpes infections.

About GEN-004
GEN-004 is a potential universal pneumococcal vaccine, which contains three unique conserved pneumococcal protein antigens, SP0148, SP1912, and SP2108, shown by ATLAS™ to be associated with protective TH17 T cell responses against pneumococcus in humans. For more information about GEN-004, please visit

About Streptococcus pneumoniae
Streptococcus pneumoniae (also known as pneumococcus) is a major cause of infectious disease-related death worldwide. The World Health Organization (WHO) estimates that up to 1.6 million people, including 800,000 children, die annually worldwide from pneumococcal infection.

Pneumococcus naturally colonizes the nasopharynx, or nose and throat, as a precursor to infection. Pneumococcus causes non-invasive pneumococcal disease (NIPD) when it spreads from the nasopharynx into the upper and lower respiratory system to cause diseases such as otitis media (ear infection) and non-bacteremic pneumonia. When it enters the bloodstream, pneumococcus can cause invasive pneumococcal disease (IPD), including life-threatening illnesses such as sepsis, meningitis and bacteremic pneumonia.

In childhood, immunity to pneumococcus is developed prior to the establishment of protective antibody responses. Scientists believe that this immunity is driven by a rare type of T cells called TH17 CD4+ T cells, which prevent establishment of disease by clearing pneumococcus from the nasopharynx.

About Genocea
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended pending further data analysis and consultation with our advisers), and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at

Forward-Looking Statements
Statements herein relating to future business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including Genocea's ability to progress any product candidates in preclinical or clinical trials; the ability of ATLAS to identify promising oncology vaccine and immunotherapy product candidates; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; anticipated clinical trial results; current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, regulatory authorities may require additional studies for approval and the product may not prove to be safe and efficacious; Genocea's ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; risks associated with the manufacture and supply of clinical and commercial product; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; Genocea's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the rate of cash utilized by Genocea in its business and the period for which existing cash will be able to fund such operation; Genocea's ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; the availability of qualified personnel and other factors set forth under "Risk Factors" in Genocea's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and other filings with the Securities and Exchange Commission (the "SEC"). Further information on the factors and risks that could affect Genocea's business, financial conditions and results of operations is contained in Genocea's filings with the SEC, which are available at These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements.

For media:

Liz BryanSpectrum Science Communications

O: 202-587-2526

For investors:

Jonathan PooleGenocea Biosciences

O: 617-876-8191

Primary Logo

Source: Genocea Biosciences

News Provided by Acquire Media